Citations

Clear

690 citation(s) found for "Abramson, V".

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01
Borad, Mitesh J. , Busset, Michele Droz Dit , Javle, Milind , Shaib, Walid L. , Personeni, Nicola , Mody, Kabir , Bergamo, Francesca, Harris, William P., Damjanov, Nevena , Macarulla, Teresa , Brandi, Giovanni , Masi, Gianluca , Abou‐Alfa, Ghassan K. , Hálfdánarson, Þorvarður R. , Knox, Jennifer, Tam, Vincent C. , Bernat, Mathieu, Engelhardt, Marc , Friedmann, Silke, Häckl, Manuel, McKernan, Phil, Saulay, Mikael, Goff, Laura W. , Hollebecque, Antoine , Adeva, Jorge , Jeffry Evans, Thomas R. , Bridgewater, John , Foerster, Friedrich , Kendall, Stephan DiSean, Roth, Gaël , Cunningham, David, Vogel, Arndt , Niger, Monica , Mahipal, Amit , Mazzaferro, Vincenzo

Mayo Clinic

Hepatology | October 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001902 | PMID 42937546 Get It

Background & Aims: To evaluate safety and efficacy of FGFR1–3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements ( FGFR2 F ), mutations ( FGFR2 M ), or amplifications ( FGFR2 A ), previously treated with chemotherapy. Approach & Results: Open-label, non-controlled Phase 2 trial. Patients with advanced iCCA, ≥1 prior chemotherapy, and FGFR2 F (Substudy 1) or FGFR2 M /FGFR A (Substudy 2), received once-daily oral derazantinib 300 mg until disease progression, unacceptable toxicity, consent withdrawal or investigator decision to stop. Efficacy was assessed by central radiology review using RECIST v1.1. Primary endpoints were objective response rate (ORR; Substudy 1) and 3-month progression-free survival (PFS3; Substudy 2). Other endpoints were PFS, ORR (Substudy 2), disease control rate (DCR), duration of response (DOR), and overall survival (OS). In Substudy 1, ORR and DCR were 22.3% (23/103 partial responses) and 75.7%, respectively; median (95% CI) PFS was 8.1 (5.5,8.3) months, DOR was 6.5 (4.6,9.2) months, and OS was 17.2 (12.5,22.4) months. In Substudy 2, PFS3 was 63% (27/43), ORR was 9.3% (3 partial, 1 complete response), DCR was 69.8%, and OS was 11.9 (8.4,15.9) months. There were no Grade 4 or 5 drug-related events. FGFR inhibitor class-specific toxicities included drug-related hyperphosphataemia (38%, Grade 3: 3%) and dry eye (36%). Nail disorders (10%, any grade or causality), stomatitis (5%), retinal events (5%), and palmar-plantar erythrodysesthesia (1%) were infrequent. Conclusions: In previously chemotherapy treated, FGFR-inhibitor-naïve patients with iCCA harboring FGFR2 fusions, mutations, or amplifications, derazantinib showed clinically meaningful efficacy with durable objective responses, and a manageable safety profile.
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia
Noll, Julia Han , Dersh, Devin , Li, Jiang Yuan, Hemani, Humza , Lavorando, Maya, Bartoszek, Robert, Amses, Kevin R. , Jain, Ankita , Minehart, Janna , Shestov, Max A, Camerini, Elena , Loren, Alison W., Woyach, Jennifer A. , Goronzy, Jorg Josef, Kater, Arnon P. , Porter, David L., Bushman, Frederic D, Levine, Bruce L. , June, Carl H. , Long, Meixiao, Weng, Nan‐ping , Diorio, Caroline, Ramirez-Fernandez, Angel , Paruzzo, Luca , Camerini, Elena , Peters, Fleur S , Huang, Xiao , Woyach, Jennifer A , Kater, Arnon P , Ruella, Marco , Byrd, John C , Schuster, Stephen J , Siegel, Donald L , Levine, Bruce L , June, Carl H , Frey, Noelle V , Cohen, Adam D , Garfall, Alfred L , Long, Meixiao , Maus, Marcela V , Weng, Nan-Ping , Fraietta, Joseph A , Bartoszek, Robert L. , Ho, Matthew , Paruzzo, Luca , Shestov, Max, Loren, Alison W. , Goronzy, Jörg J. , Ruella, Marco , Byrd, John C. , Powell, Daniel J. , Gill, Saar , Porter, David L. , Schuster, Stephen J. , Bushman, Frederic D. , Frey, Noelle V. , Cohen, Adam D. , Garfall, Alfred L. , Diorio, Caroline J.

Mayo Clinic

Blood Journal | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025032274 | PMID 42636161 Get It

CD19-directed CAR T-cells (CTL019) can produce durable remissions in chronic lymphocytic leukemia (CLL), but therapeutic success depends on whether autologous T-cells expand, persist, and retain cytotoxic function after manufacturing. Failure of CLL T-cells is often attributed to exhaustion, although many dysfunctional CLL T-cells retain inflammatory cytokine production. We tested whether this paradox reflects immunosenescence, an aging-like program defined by costimulatory loss, DNA damage, inflammatory secretion, repertoire restriction, and proliferative arrest. In response-linked preinfusion CTL019 products, nonresponders and short partial responders had higher senescence and senescence-associated secretory phenotype (SASP) programs than the functional-responder group, comprising complete responders and partial responders with transformed disease. These programs were detectable before infusion and became more prominent during manufacture in susceptible products. They tracked with weak in vivo CAR T-cell expansion and were associated with inferior survival. Serum proteomics revealed a circulating, CLL-associated SASP-like inflammatory milieu in nonresponders. Flow cytometry and T-cell receptor (TCR) profiling showed that poor responders carried CD27⁻CD28⁻ and KLRG1⁺ CD8 T-cells at apheresis, lower product CD27, and reduced product TCR diversity. Research-manufactured CAR T-cells from treatment-naïve CLL samples displayed the same state, most prominently in CD4 CAR T-cells, with SA-β-gal, p16, p53, DNA damage, depletion of less-differentiated states, and senescence-enriched transcriptomes. Under repeated CD19 stimulation, CLL-derived products reached a proliferative ceiling, and p53-high products lost cytotoxic reserve. Ibrutinib improved proliferative fitness, attenuated senescence-associated features and SASP output in paired patient and direct-exposure assays, and enhanced CAR T-cell expansion in an ibrutinib-resistant CLL model. Together, these data identify immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in CLL and a candidate for therapeutic modulation.
NCCN Guidelines® Insights: Survivorship, Version 3.2026
Peterson, L., McDonough, Allison L. , Ansbaugh, Shannon M., Heredia, Ella J. Ariza, Armenian, Saro, Baker, K. Scott, Cathcart-Rake, Elizabeth J., Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine, Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Hock, Karen, Kline-Quiroz, Cristina, Lee, Nita K., Mooney, Kathi, Moryl, Natalie , Neuman, Heather, Overholser, Linda, Patel, Chirayu G. , Porpiglia, Andrea, Saidain, Ava, Schapira, Lidia , Smith, Sophia K., Tenner, Laura, Ah, Diane Von , Zee, Phyllis, Freedman-Cass, Deborah, McMillian, Nicole, Ariza‐Heredia, Ella , Armenian, Saro H. , Ballinger, Tarah Jean , Cathcart-Rake, Elizabeth , Day, Andrew T. , Evgeniou, Evgenios , Feliciano, Josephine , Friedman, Debra L. , Hock, Karen , Kline‐Quiroz, Cristina , Moore, Halle C. F. , Neuman, Heather B. , Overholser, Linda , Porpiglia, Andrea S., Rogers, Laura Q. , Yang, Eric H. , Freedman-Cass, Deborah A., McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0039 | PMID 42607712 Get It

The NCCN Guidelines for Survivorship offer guidance for health care providers who care for survivors of adult-onset cancer. These guidelines include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from cancer and its treatment and provide a framework for care coordination. They also present guidance for helping cancer survivors to enhance their wellness and maintain a healthy lifestyle. This article summarizes the panel’s current recommendations and recent updates regarding anxiety, depression, distress, and trauma in cancer survivors.
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Stevenson, James, Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Dowell, Jonathan, Durm, Gregory A. , Gettinger, S., Grotz, Travis E., Gubens, Matthew A., Lackner, Rudy P., Lanuti, Michael, Levy, Benjamin, Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C., Ng, Thomas, Owen, Dawn , Owen, Dwight H., Patil, Tejas, Polanco, Patricio M., Riess, Jonathan, Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Tam, Alda, Yau, Edwin, Yun, Karen, Gregory, Kristina, Hang, Lisa, Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bauman, Jessica R. , Bharat, Ankit , Gettinger, Scott , Grotz, Travis E. , Gubens, Matthew A. , Juloori, Aditya , Levy, Benjamin , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Mullikin, Trey C. , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yau, Edwin , Yun, Karen M. , Gregory, Kristina M., Hang, Lisa E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0038 | PMID 42607715 Get It

Mesothelioma is a rare cancer that originates from the mesothelial surfaces of certain sites within the body. Pleural mesothelioma is the most common type and represents approximately 85% of mesotheliomas. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for evaluation and treatment in patients with pleural mesothelioma. The NCCN Guidelines will continue to be updated annually based on available clinical evidence and panel consensus.
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R, Jones, Richard J., Singh, Anurag K, Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J., Üstün, Celalettin , Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias, Onozawa, Masahiro , Thomson, Kirsty , Chen, Caroline , Hasabou, Nahla, Rosales, Matt, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Mendizabal, Adam , Horowitz, Mary M, Chen, Yi‐Bin , Papadopoulos, Esperanza , Perl, Alexander E , Ustun, Celalettin , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Muffly, Lori , Kim, Hee-Je , Najima, Yuho , Onozawa, Masahiro , Hill, Jason , Devine, Steven , Chen, Yi-Bin , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Wingard, John R. , Soiffer, Robert J. , Ueda, Masumi , Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Stelljes, Matthias , Hill, Jason E. , Devine, Steven M. , Horowitz, Mary M.

Mayo Clinic

Blood Advances | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020327 | PMID 42532509 Get It

BMT CTN 1506 ("MORPHO") was a phase 3 study of post-hematopoietic cell transplantation (HCT) maintenance with gilteritinib versus placebo for patients with FLT3-ITD-mutated acute myeloid leukemia (AML) in first remission. Subgroup analysis indicated a significant benefit of post-HCT gilteritinib for participants in North America, but no benefit for those in Europe or Asia. We conducted a post-hoc analysis of the data focusing on days from AML diagnosis to HCT, pre-HCT FLT3 inhibitor use, and FLT3-ITD measurable residual disease (MRD). Participants transplanted < 120 days from AML diagnosis and/or those treated with FLT3 inhibition pre-HCT were more likely to have improved survival from post-HCT gilteritinib. Pre-HCT MRD levels were higher (P = 0.001) in participants transplanted within 120 days from diagnosis and in those treated with a FLT3 inhibitor pre-HCT and transplanted within 120 days (P = 0.008). Pre-HCT MRD was dependent on both FLT3 inhibitor use and time to HCT, as participants treated with successive courses of chemotherapy + FLT3 inhibition had successively lower MRD by the time of HCT. Time from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use both appeared to impact MRD levels immediately prior to HCT, and geographic differences in these two practice patterns likely accounted for the observed regional differences in benefit from post-HCT gilteritinib. Increasing the number of courses of treatment pre-HCT may lower MRD sufficiently to eliminate the need for post-HCT inhibition, but with a presumed risk of some patients experiencing early progression. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
Guidelines for Pediatric Radiotherapy Simulation: A Report From the Children's Oncology Group Radiation Oncology Discipline
Alaei, Parham , Mihalcik, Stephen, Baliga, Sujith , Kwok, Young , Casey, Dana L. , Ehler, Eric, Burton, Christiane, Breneman, John C., Haas-Kogan, D., Laack, Nadia N., Milgrom, Sarah, Hill‐Kayser, Christine, Kalapurakal, John A., Hua, Chia-Ho, Ehler, E , Casey, Dana L , Mihalcik, Stephen A. , Burton, Christiane Sarah , Breneman, John C. , Haas-Kogan, Daphne , Wolden, Suzanne L. , Paulino, Arnold C. , Laack, Nadia N. , Esiashvili, Natia , Hill‐Kayser, Christine E. , FitzGerald, Thomas J. , Kalapurakal, John A.

Mayo Clinic

Pediatric Blood & Cancer | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/1545-5017.70460 | PMID 42520295 Get It

ABSTRACT Pediatric radiation therapy presents unique challenges compared to adult treatments, including those of immobilization, potential need for sedation, and the critical importance of accurate, reproducible positioning. Additionally, heightened attention to imaging doses is necessary to minimize long‐term toxicity in survivors. Many of these challenges must be addressed during the process of simulation. This report provides guidelines for pediatric radiotherapy simulation from the Children's Oncology Group. These guidelines cover all anatomic sites and include recommendations for photon and proton therapies, as well as specialized procedures such as stereotactic body radiation therapy, brachytherapy, and total body irradiation. These guidelines are presented as recommendations rather than prescriptive standards as the practice will vary depending on patient age, diagnosis, clinical judgment, and institutional resources.
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004
Wierda, William G. , Dorritie, Kathleen , Gauthier, Jordan , Nath, Rajneesh, Kipps, Thomas J. , Riedell, Peter A. , Eradat, Herbert A., Kharfan‐Dabaja, Mohamed A. , Shah, Nirav N. , Solomon, Scott R., Stephens, Deborah M., Ermann, Daniel A., Arnason, Jon , Deol, Abhinav , Feldman, Tatyana , Ghosh, Monalisa , Tuazon, Sherilyn A., Perna, Serena K., Ou, San-San, Ananthakrishnan, Revathi , Rane, Neha, Papp, Eniko, Ansari, Sahar , Thompson, Ethan G., Okal, Abood, Peiser, Leanne, Chen, Yizhe , Sengupta, Sanhita , Wang, Jixian , Wierda, William G. , Dorritie, Kathleen , Kenderian, Saad S. , Kharfan-Dabaja, Mohamed A , Shah, Nirav N , Deol, Abhinav , Ma, Shuo , Schuster, Stephen J , Gergis, Usama , Vose, Julie , Soumerai, Jacob D , Besien, Koen van , Chen, Yizhe , Sengupta, Sanhita , Ray, Pradipta Ranjan , Siddiqi, Tanya , Kipps, Thomas J , Riedell, Peter A , Nath, Rajneesh , Eradat, Herbert, Stephens, Deborah M. , Andreadis, Charalambos Babis , Ma, Shuo , Schuster, Stephen J. , Vose, Julie M. , Soumerai, Jacob D. , Tuazon, Sherilyn A. , Perna, Serena , Ou, San‐San , Papp, Eniko , Ansari, Sahar, Siddiqi, Tanya

Mayo Clinic

Blood Journal | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033565 | PMID 42520199 Get It

Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1] or 100×106 [DL2] chimeric antigen receptor-positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n=5; DL2, n=51), median (range) age was 64.5 years (44‒77), 98% had high-risk cytogenetics, 55% had progression on Bruton tyrosine kinase inhibitor and venetoclax failure, and median (range) number of prior therapies was 5 (1‒13). Median (range) follow-up was 24.8 months (3.1‒51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31‒60) and overall response rate was 86% (95% CI, 74‒94). Median (95% CI) duration of response was not reached (NR; 28.7‒NR) for patients with CR/CRi and 41.4 months (23.3‒NR) for all responders. Median (95% CI) progression-free survival was 31.4 months (20.1‒NR). In DL1+DL2, most common grade ≥3 treatment-emergent adverse events (TEAE) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of patients (grade 3, 4%; no grade 4/5), and neurological events in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with relapsed/refractory CLL/SLL with predictable and manageable safety. Clinicaltrials.gov: NCT03331198; NCT03435796.
MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD
Sebastian, Tara, Weber, Daniela, Etra, Aaron M., Vasova, Ingrid, Ayuk, Francis, Choe, Hannah K., DeFilipp, Zachariah, Quagliarella, Francesco, Bedirian, Karni, Diniz, Marcio Augusto, Aguayo-Hiraldo, Paibel, Bader, Peter, Baez, Janna, Chanswangphuwana, Chantiya, Eng, Gilbert, Francke, Thomas, Hexner, Elizabeth O., Katsivelos, Nikolaos, Kitko, Carrie L., Kraus, Sabrina, Louloudis, Ioannis E., Morales, George, Nakamura, Ryotaro, Olson, Timothy S., Qayed, Muna, Reddy, Pavan, Reshef, Ran, Schechter, Tal, Wang, Tingyu, Wolf, Matthias, Young, Rachel, Zeiser, Robert, Hogan, William J., Levine, John E., Ferrara, James L.M., Sebastian, Tara M. , Weber, Daniela , Etra, Aaron , Vášová, Ingrid, Ayuk, Francis , Choe, Hannah , DeFilipp, Zachariah , Quagliarella, Francesco , Bedirian, Karni, Aguayo‐Hiraldo, Paibel , Bader, Peter , Baez, Janna , Chanswangphuwana, Chantiya , Eng, Gilbert, Francke, Thomas, Hexner, Elizabeth O. , Katsivelos, Nikolaos , Kitko, Carrie L. , Kraus, Sabrina , Morales, George , Nakamura, Ryotaro , Olson, Timothy S. , Qayed, Muna , Reddy, Pavan, Reshef, Ran , Schechter, Tal , Wölfl, Matthias , Young, Rachel , Zeiser, Robert , Hogan, William J. , Levine, John E. , Ferrara, James L.M.

Mayo Clinic

No container title available | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.09.26357664 | PMID 42523406 Get It

ABSTRACT Approximately 30% of patients with acute graft-versus-host disease (GVHD) develop steroid-refractory disease and have very poor outcomes. Ruxolitinib has become the standard of care for steroid-refractory acute GVHD, but it is unclear which patients derive benefit. The MAGIC Composite Score (MCS), an algorithm that combines clinical symptoms and biomarkers, has been validated to predict outcomes at the start of primary GVHD treatment. Here, we evaluated its performance at the initiation of second-line treatment in 278 patients. MCS stratified patients into three risk groups (MCS1-3), with the majority (88%) classified as intermediate or high risk. Increasing MCS score was associated with progressively higher 1-year non-relapse mortality (NRM) rates (16%, 41%, and 73%; p<0.001), lower 1-year survival (77%, 56%, and 24%; p<0.001), and lower complete response (CR) rates at day 28 (47%, 38%, and 20%, respectively; p<0.01). The area under the receiver operating characteristic curve (AUROC) for 1-year NRM was significantly higher with MCS compared to clinical symptoms alone (0.70 vs. 0.63; p=0.023). Among patients treated with ruxolitinib, higher MCS similarly predicted higher NRM and lower survival and CR rates. Patients classified as MCS2/3 had poor outcomes despite ruxolitinib, underscoring the need for novel therapies in this patient population. In conclusion the MCS is an accurate predictor of outcomes for patients who require second-line treatment and may be of use as an eligibility criterion for future clinical trials in this high-risk population. Key Points MAGIC Composite Scores that integrate clinical symptoms and biomarker scores predict outcomes of second-line therapy for acute GVHD more accurately than clinical symptoms alone. MCS identifies patients with high NRM despite treatment with ruxolitinib.
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
Gerds, Aaron T., Gotlib, J, Abdelmessieh, Peter, Ali, Haris, Castells, Mariana, Chernak, Brian , Espinoza-Gutarra, Manuel R., Revell, Rebecca, Green, Steven, Gundabolu, Krishna , Hexner, Elizabeth, Jamieson, Catriona H., Khan, Irum, Kuykendall, Andrew T., McMahon, Brandon, Mohan, Sanjay R., Nadiminti, Kalyan V., Oh, Stephen, Palmer, Jeanne, Patel, Ami B. , Patel, Anand A., Rein, Lindsay, Salit, Rachel, Sehl, Mary, Wadleigh, Martha, Wall, Sarah A., Bergman, Mary Anne, Hochstetler, Cindy, Patel, Anand , Patel, Anand , Gerds, Aaron T. , Gotlib, Jason , Ali, Haris , Espinoza‐Gutarra, Manuel , Green, S, Hexner, Elizabeth O. , Jain, Tania , Khan, Irum , Kuykendall, Andrew , Madanat, Yazan F. , Masárová, Lucia , Mohan, Sanjay R., Nadiminti, Kalyan, Palmer, Jeanne , Podoltsev, Nikolai , Salit, Rachel B. , Sehl, Mary E. , Talpaz, Moshe , Wadleigh, Martha , Wall, Sarah

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0034 | PMID 42425157 Get It

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a group of heterogenous hematologic malignancies characterized by the proliferation of blood cells and consist of myelofibrosis, polycythemia vera, and essential thrombocythemia. The NCCN Guidelines for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the aim of providing recommendations for the comprehensive care of adults with these diseases. The panel of experts convenes at least once a year to discuss requested changes to the Guidelines and to evaluate emerging data. These Guideline Insights focus on some of the recent updates for myelofibrosis.
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Gradishar, W J, Moran, Meena S. , Abraham, Jame , Abramson, Vandana, Aft, Rebecca, Agnese, Doreen, Allison, Kimberly H., Anderson, Bethany, Bailey, Janet, Burstein, Harold J. , Chen, Nan , Chew, Helen, Dang, Chau, Giordano, Sharon H., Goetz, Matthew P., Jankowitz, Rachel C., Javid, Sara H., Leitch, A. Marilyn, LYONS, JANICE, McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Rosenberger, Laura H., Santa‐Maria, Cesar A. , Schneider, Bryan P., Smith, Mary Lou , Soliman, Hatem, Speers, Corey, Telli, Melinda L. , Wei, Mei , Wisinski, Kari B., Yellala, Amulya, Schonfeld, Ryan, Telli, Melinda L , Gradishar, William John, Abramson, Vandana G. , Agnese, Doreen Marie , Allison, Kimberly H. , Bailey, Janet E., Chew, Helen K. , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Schneider, Bryan P. , Soliman, Hatem, Speers, Corey , Wisinski, Kari B. , Yeung, Kay T. , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0033 | PMID 42425164 Get It

The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factors such as prior therapy and disease-free interval. Throughout all treatment lines, supportive care, quality of life preservation, toxicity minimization, and clinical trial participation are emphasized as integral components of patient care.